Partial Remission in Pediatric Relapsed Neuroblastoma After Multiple Cycle Low-Dose 211At-MABG Therapy

Area of Science:

• Nuclear medicine
• Pediatric oncology
• Radiopharmaceutical therapy

Background:

• Neuroblastoma is a common pediatric cancer.
• Relapsed neuroblastoma has a poor prognosis.
• Current therapies for relapsed neuroblastoma are limited.

Purpose of the Study:

• To evaluate the safety and efficacy of 211At-MABG-targeted alpha therapy in a pediatric patient with relapsed neuroblastoma.
• To assess the feasibility of repeated, low-dose administration of 211At-MABG.

Main Methods:

• A single pediatric patient with relapsed, metastatic neuroblastoma was treated with escalating doses of 211At-MABG-targeted alpha therapy.
• Treatment response was assessed using 18F-MFBG PET/CT scans and Curie scoring.
• Safety and tolerability were monitored throughout the treatment course.

Main Results:

• The patient showed a significant reduction in bone metastases and tracer uptake after treatment, with a decrease in Curie score from 4 to 1.
• The therapy was well-tolerated, with no significant adverse events reported.
• Repeated administrations of low-dose 211At-MABG were feasible.

Conclusions:

• 211At-MABG-targeted alpha therapy shows promise as a safe and effective treatment for pediatric relapsed neuroblastoma.
• This approach may offer a new therapeutic option for patients with limited treatment alternatives.
• Further investigation in larger trials is warranted to confirm these findings.